Michael Montalto, Amgen | How to have the biggest impact on patients: a career of invention, innovation, and implementation | TPM podcast #48
Today on the show, I’m joined by Michael Montalto, vice president of precision medicine at Amgen. Amgen is widely recognized as one of the most successful pharmaceutical companies in translating research and development into approved therapies. A key part of that success comes from their focus on precision medicine, and Mike brings a unique perspective from the forefront of that work.TPM E48 highlights >Episode 48 links:AmgenMichael Montalto on LinkedInGenialis presents a poster at ISMB/ECCB 2025
--------
43:24
--------
43:24
Stéphane Budel, DeciBio | Precision medicine is our future and our fate | TPM podcast #46
Stéphane Budel, founding partner at DeciBio, joins the Talking Precision Medicine Podcast to explore the future of the field. He unpacks how liquid biopsy, multi-omics, and AI are opening new doors for personalized care, why the diagnostics business model is holding innovation back, and what it will take to make complex tech usable for clinicians and patients alike.TPM E46 highlights >Episode 46 links:DeciBioStephane Budel on LinkedInDeciBio’s White Paper on AI in Drug Development (with contributions from Rafael Rosengarten)
--------
50:02
--------
50:02
Anna Berkenblit & Sudheer Doss, PanCAN | On a mission to beat an ignoble killer: pancreatic cancer | TPM podcast #45
Today’s guests are Anna Berkenblit, Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network, and Sudheer Doss, Chief Business Officer at PanCAN. The Pancreatic Cancer Action Network is the leading organization dedicated to advancing progress against pancreatic cancer. It empowers patients and caregivers, drives early detection strategies, and revolutionizes the development of advanced and personalized treatments.TPM E45 highlights >Episode 45 links:Anna Berkenblit on LinkedInSudheer Doss on LinkedInPanCANFor access to data through PanCAN’s SPARK platform, please visit: PanCAN.org/sparkFor more information, contact PanCAN Patient Services with questions about any type of pancreatic cancer – we are here to help.
--------
46:10
--------
46:10
Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44
Today’s guest is Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals.Recursion is widely recognized as one of the most visible—and so far, most successful—companies to emerge from the tech-bio movement. Many consider it the current industry leader.It has become an iconic name in the field of artificial intelligence for drug discovery.TPM E44 highlights >Episode 44 links:Najat Khan on LinkedInRecursion
--------
38:35
--------
38:35
Ryan Fukushima | Reinventing diagnostics: The superpower of not knowing what can’t be done | TPM #43
What a pleasure to welcome today’s guest, Ryan Fukushima, chief operating officer of TempusAI. Not only has Ryan helped build Tempus brick by brick from the earliest days, he is also CEO of Pathos AI, a biotech company using real world data and AI to develop true precision medicines. I don’t know how he juggles it all, but unless you’ve been hiding out these last few years, Tempus has become a household name in our industry, completing a highly successful IPO last year. But no need to take my word for it, come on in and have a listen!TPM E43 highlights >Episode 43 links:Ryan Fukushima on LinkedInTempus AIPathosTempus announces multi-year collaboration with Genialis
Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.
Netherlands